|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
CA2859785A1
(en)
*
|
2011-12-21 |
2013-06-27 |
Amgen Inc. |
Variant fc-polypeptides with enhanced binding to the neonatal fc receptor
|
|
CA2898100C
(en)
|
2013-01-14 |
2023-10-10 |
Xencor, Inc. |
Novel heterodimeric proteins
|
|
JO3519B1
(ar)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US9212225B1
(en)
|
2014-07-01 |
2015-12-15 |
Amphivena Therapeutics, Inc. |
Bispecific CD33 and CD3 binding proteins
|
|
AU2015294834B2
(en)
|
2014-07-31 |
2021-04-29 |
Amgen Research (Munich) Gmbh |
Optimized cross-species specific bispecific single chain antibody constructs
|
|
AR101669A1
(es)
*
|
2014-07-31 |
2017-01-04 |
Amgen Res Munich Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
|
WO2016019969A1
(en)
|
2014-08-08 |
2016-02-11 |
Ludwig-Maximilians-Universität München |
Subcutaneously administered bispecific antibodies for use in the treatment of cancer
|
|
CA2963696A1
(en)
*
|
2014-10-09 |
2016-04-14 |
Engmab Ag |
Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer
|
|
RS60615B1
(sr)
*
|
2014-11-20 |
2020-08-31 |
Hoffmann La Roche |
Zajednički laki lanci i postupci upotrebe
|
|
ES2926673T3
(es)
|
2014-11-20 |
2022-10-27 |
Hoffmann La Roche |
Politerapia de moléculas de unión a antígeno biespecíficas activadoras de linfocitos T y antagonistas de la unión al eje de PD-1
|
|
SG11201702976TA
(en)
*
|
2014-11-20 |
2017-05-30 |
Hoffmann La Roche |
T cell activating bispecific antigen binding molecules agiant folr1 and cd3
|
|
HRP20211273T1
(hr)
|
2014-11-26 |
2021-11-12 |
Xencor, Inc. |
Heterodimerna protutijela koja vežu cd3 i cd20
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
MX2017006918A
(es)
|
2014-11-26 |
2018-01-25 |
Xencor Inc |
Anticuerpos heterodimericos que se unen a cd3 y cd38.
|
|
SG11201704449VA
(en)
|
2014-12-05 |
2017-06-29 |
Genentech Inc |
ANTI-CD79b ANTIBODIES AND METHODS OF USE
|
|
WO2016094881A2
(en)
*
|
2014-12-11 |
2016-06-16 |
Abbvie Inc. |
Lrp-8 binding proteins
|
|
US20160175458A1
(en)
*
|
2014-12-19 |
2016-06-23 |
Alkermes, Inc. |
Single chain fc fusion proteins
|
|
TN2018000324A1
(en)
|
2015-01-23 |
2020-01-16 |
Sanofi Sa |
ANTl-CD3 ANTIBODIES, ANTl-CD123 ANTIBODIES AND BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO CD3 AND/OR CD123
|
|
CA2974720A1
(en)
|
2015-02-06 |
2016-08-11 |
University Of Maryland, Baltimore |
Tetra-specific, octameric binding agents and antibodies against clostridium difficile toxin a and toxin b for treatment of c. difficile infection
|
|
AR104309A1
(es)
|
2015-04-17 |
2017-07-12 |
Bayer Pharma AG |
Construcciones de anticuerpos biespecíficos para cdh3 y cd3
|
|
KR20190080992A
(ko)
|
2015-05-21 |
2019-07-08 |
하푼 테라퓨틱스, 인크. |
삼중특이성 결합 단백질 및 사용 방법
|
|
JP2018516248A
(ja)
*
|
2015-05-29 |
2018-06-21 |
アンフィヴェナ セラピューティクス，インク． |
二重特異性のｃｄ３３およびｃｄ３結合タンパク質を使用する方法
|
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
|
|
FR3038517B1
(fr)
*
|
2015-07-06 |
2020-02-28 |
Laboratoire Francais Du Fractionnement Et Des Biotechnologies |
Utilisation de fragments fc modifies en immunotherapie
|
|
TWI793062B
(zh)
|
2015-07-31 |
2023-02-21 |
德商安美基研究（慕尼黑）公司 |
Ｄｌｌ３及ｃｄ３抗體構築體
|
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究（慕尼黑）公司 |
Ｍｓｌｎ及ｃｄ３抗體構築體
|
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究（慕尼黑）公司 |
Ｆｌｔ３及ｃｄ３抗體構築體
|
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究（慕尼黑）公司 |
Egfrviii及cd3抗體構築體
|
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究（慕尼黑）公司 |
Ｃｄ７０及ｃｄ３抗體構築體
|
|
EA039859B1
(ru)
|
2015-07-31 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
|
JO3620B1
(ar)
|
2015-08-05 |
2020-08-27 |
Amgen Res Munich Gmbh |
مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
IL313507A
(en)
|
2016-02-03 |
2024-08-01 |
Amgen Res Munich Gmbh |
Constructs of bispecific antibodies to BCMA and CD3 that bind to T cells, preparations containing the same and uses thereof
|
|
IL260920B
(en)
|
2016-02-03 |
2022-09-01 |
Amgen Res Munich Gmbh |
Constructs of psma and cd3 bispecific antigens that bind to t-cells, preparations containing them and uses thereof
|
|
GB201604458D0
(en)
|
2016-03-16 |
2016-04-27 |
Immatics Biotechnologies Gmbh |
Peptides and combination of peptides for use in immunotherapy against cancers
|
|
BR112018016281A2
(pt)
*
|
2016-03-22 |
2019-01-02 |
F. Hoffmann-La Roche Ag |
molécula biespecífica ativadora de célula t ativável por protease, polipeptídeo idiotipo-específico, composição farmacêutica, usos da molécula biespecífica e método de tratamento de uma doença em um indivíduo
|
|
LT3433280T
(lt)
|
2016-03-22 |
2023-07-10 |
F. Hoffmann-La Roche Ag |
Proteazės aktyvuojamos t ląstelei bispecifinės molekulės
|
|
JOP20170091B1
(ar)
|
2016-04-19 |
2021-08-17 |
Amgen Res Munich Gmbh |
إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
|
|
PL3461261T3
(pl)
|
2016-05-20 |
2025-11-12 |
Harpoon Therapeutics, Inc. |
Białka wiążące jednołańcuchowy fragment zmienny CD3
|
|
EP3493844A4
(en)
|
2016-05-20 |
2021-03-24 |
Harpoon Therapeutics Inc. |
SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
SG11201811184UA
(en)
|
2016-06-20 |
2019-01-30 |
F Star Beta Ltd |
Lag -3 binding members
|
|
JP7084881B2
(ja)
|
2016-06-22 |
2022-06-15 |
アルカームス インコーポレーテッド |
Ｉｌ－１０の免疫刺激特性および抗炎症特性を調節するための組成物および方法
|
|
EP3475304B1
(en)
|
2016-06-28 |
2022-03-23 |
Xencor, Inc. |
Heterodimeric antibodies that bind somatostatin receptor 2
|
|
MX2019006045A
(es)
|
2016-11-23 |
2019-11-11 |
Harpoon Therapeutics Inc |
Proteinas triespecificas dirigidas a psma y metodos de uso.
|
|
KR20210087108A
(ko)
|
2016-11-23 |
2021-07-09 |
하푼 테라퓨틱스, 인크. |
전립선 특이 막 항원 결합 단백질
|
|
JOP20190189A1
(ar)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
|
|
US11535668B2
(en)
|
2017-02-28 |
2022-12-27 |
Harpoon Therapeutics, Inc. |
Inducible monovalent antigen binding protein
|
|
TWI868050B
(zh)
|
2017-05-05 |
2025-01-01 |
美商安進公司 |
用於改良儲存及投與之包含雙特異性抗體構築體之醫藥組成物
|
|
CA3063362A1
(en)
*
|
2017-05-12 |
2018-11-15 |
Harpoon Therapeutics, Inc. |
Msln targeting trispecific proteins and methods of use
|
|
SG10202107880XA
(en)
|
2017-05-12 |
2021-09-29 |
Harpoon Therapeutics Inc |
Mesothelin binding proteins
|
|
PL3694529T3
(pl)
|
2017-10-13 |
2024-12-16 |
Harpoon Therapeutics, Inc. |
Trójswoiste białka i sposoby zastosowania
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
IL321773A
(en)
|
2017-10-14 |
2025-08-01 |
Cytomx Therapeutics Inc |
Activatable antibodies and methods for preparing them
|
|
WO2019094637A1
(en)
|
2017-11-08 |
2019-05-16 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-pd-1 sequences
|
|
CN111315780A
(zh)
|
2017-12-11 |
2020-06-19 |
安进公司 |
双特异性抗体产品的连续制造工艺
|
|
AU2018387829B2
(en)
|
2017-12-22 |
2024-12-19 |
Argenx Bvba |
Bispecific antigen binding construct
|
|
CN109957026A
(zh)
*
|
2017-12-22 |
2019-07-02 |
成都恩沐生物科技有限公司 |
共价多特异性抗体
|
|
TW201940518A
(zh)
|
2017-12-29 |
2019-10-16 |
美商安進公司 |
針對ｍｕｃ１７和ｃｄ３之雙特異性抗體構建體
|
|
GB201802487D0
(en)
|
2018-02-15 |
2018-04-04 |
Argenx Bvba |
Cytokine combination therapy
|
|
CN112469477A
(zh)
|
2018-04-04 |
2021-03-09 |
Xencor股份有限公司 |
与成纤维细胞活化蛋白结合的异源二聚体抗体
|
|
CN108610417B
(zh)
*
|
2018-04-28 |
2021-01-26 |
暨南大学 |
抗破伤风毒素中和抗体、其制备方法及用途
|
|
MX2020012217A
(es)
|
2018-05-14 |
2021-03-02 |
Harpoon Therapeutics Inc |
Porción de unión para activación condicional de moléculas de inmunoglobulina.
|
|
AU2019301204B2
(en)
|
2018-07-12 |
2025-10-23 |
Invox Pharma Limited |
Antibody molecules that bind PD-L1 and CD137
|
|
GB201811408D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
CD137 Binding Molecules
|
|
GB201811410D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
OX40 Binding molecules
|
|
GB201811403D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Antibody molecules
|
|
MX2021000399A
(es)
|
2018-07-12 |
2021-05-27 |
F Star Therapeutics Ltd |
Moleculas de anticuerpo que se unen a cd137 y ox40.
|
|
GB201811450D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Delta Ltd |
Mesothelin and CD137 binding molecules
|
|
GB201811415D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-Mesothelin Anti bodies
|
|
EP3830121A1
(en)
|
2018-07-30 |
2021-06-09 |
Amgen Research (Munich) GmbH |
Prolonged administration of a bispecific antibody construct binding to cd33 and cd3
|
|
CA3105729A1
(en)
|
2018-07-31 |
2020-02-06 |
Amgen Research (Munich) Gmbh |
Dosing regimen for bcma-cd3 bispecific antibodies
|
|
UA129980C2
(uk)
|
2018-08-03 |
2025-10-01 |
Емджен Рісерч (Мюнік) Ґмбг |
Конструкція на основі антитіл для зв'язування cldn18.2 і cd3
|
|
US12195544B2
(en)
|
2018-09-21 |
2025-01-14 |
Harpoon Therapeutics, Inc. |
EGFR binding proteins and methods of use
|
|
CN113286817B
(zh)
|
2018-09-25 |
2025-01-28 |
哈普恩治疗公司 |
Dll3结合蛋白及使用方法
|
|
US11505614B2
(en)
|
2018-09-28 |
2022-11-22 |
Amgen Inc. |
Antibodies binding to soluble BCMA
|
|
SG11202103275YA
(en)
|
2018-10-11 |
2021-04-29 |
Amgen Inc |
Downstream processing of bispecific antibody constructs
|
|
SG11202103232WA
(en)
|
2018-10-23 |
2021-05-28 |
Amgen Inc |
Automatic calibration and automatic maintenance of raman spectroscopic models for real-time predictions
|
|
BR112021012338A2
(pt)
*
|
2018-12-24 |
2021-09-14 |
Sanofi |
Proteínas de ligação multiespecíficas com domínios fab mutantes
|
|
TWI871300B
(zh)
|
2019-01-28 |
2025-02-01 |
美商安進公司 |
藉由將藥物物質和藥物產品過程整體化的生物製劑製造之連續製造過程
|
|
CN113784732B
(zh)
|
2019-05-07 |
2024-03-22 |
亘喜生物科技（上海）有限公司 |
靶向bcma的工程化免疫细胞及其用途
|
|
MX2021014644A
(es)
|
2019-06-13 |
2022-04-06 |
Amgen Inc |
Control de perfusion basado en biomasa automatizado en la fabricacion de productos biologicos.
|
|
CN116987197A
(zh)
*
|
2019-06-20 |
2023-11-03 |
成都恩沐生物科技有限公司 |
共价多特异性抗体
|
|
US20210032370A1
(en)
|
2019-08-02 |
2021-02-04 |
Immatics Biotechnologies Gmbh |
Recruiting agent further binding an mhc molecule
|
|
DE102019121007A1
(de)
|
2019-08-02 |
2021-02-04 |
Immatics Biotechnologies Gmbh |
Antigenbindende Proteine, die spezifisch an MAGE-A binden
|
|
MX2022002981A
(es)
|
2019-09-10 |
2022-04-06 |
Amgen Inc |
Metodo de purificacion para polipeptidos de union a antigeno biespecificos con capacidad de union dinamica de captura de proteina l mejorada.
|
|
WO2021091906A1
(en)
|
2019-11-04 |
2021-05-14 |
Amgen Inc. |
Methods for treating leukemia
|
|
SMT202400373T1
(it)
|
2019-11-11 |
2024-11-15 |
Amgen Inc |
Regime di dosaggio per agenti anti-bcma
|
|
EP4058485A1
(en)
|
2019-11-13 |
2022-09-21 |
Amgen Inc. |
Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
|
|
NZ787541A
(en)
|
2019-11-25 |
2025-10-31 |
Alkermes Inc |
Substituted macrocyclic compounds and related methods of treatment
|
|
MX2022007688A
(es)
|
2019-12-20 |
2022-07-19 |
Amgen Inc |
Constructos de anticuerpo multiespecificos agonistas de cd40 dirigidos a mesotelina para el tratamiento de tumores solidos.
|
|
US20230132241A1
(en)
|
2020-01-15 |
2023-04-27 |
Immatics Biotechnologies Gmbh |
Antigen binding proteins specifically binding prame
|
|
EP4093771A1
(en)
|
2020-01-22 |
2022-11-30 |
Amgen Research (Munich) GmbH |
Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
|
|
WO2021158469A1
(en)
|
2020-02-03 |
2021-08-12 |
Amgen Inc. |
Multivariate bracketing approach for sterile filter validation
|
|
TWI888487B
(zh)
|
2020-02-14 |
2025-07-01 |
日商協和麒麟股份有限公司 |
與ｃｄ３結合之雙特異性抗體
|
|
KR20220144841A
(ko)
|
2020-02-21 |
2022-10-27 |
하푼 테라퓨틱스, 인크. |
Flt3 결합 단백질 및 사용 방법
|
|
TW202200615A
(zh)
|
2020-03-12 |
2022-01-01 |
美商安進公司 |
用於治療和預防患者的crs之方法
|
|
JP7750852B2
(ja)
|
2020-03-19 |
2025-10-07 |
アムジエン・インコーポレーテツド |
ムチン１７に対する抗体及びその使用
|
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
|
US20220106403A1
(en)
*
|
2020-05-14 |
2022-04-07 |
Xencor, Inc. |
Heterodimeric antibodies that bind msln and cd3
|
|
MX2022014636A
(es)
|
2020-05-19 |
2023-02-23 |
Amgen Inc |
Construcciones de unión a mageb2.
|
|
MX2022014902A
(es)
|
2020-05-29 |
2023-01-04 |
Amgen Inc |
Administracion mitigadora de efectos adversos de un constructo biespecifico que se une a cd33 y cd3.
|
|
PE20231080A1
(es)
|
2020-06-19 |
2023-07-17 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y cd19
|
|
US20240092890A1
(en)
|
2020-08-27 |
2024-03-21 |
Juntendo Educational Foundation |
Anti-cleaved mutant calr-cd3 bispecific antibody and pharmaceutical composition
|
|
MX2023003041A
(es)
|
2020-09-16 |
2023-05-09 |
Amgen Inc |
Métodos para administrar dosis terapéuticas de moléculas de acoplamiento a células t biespecíficas para el tratamiento de cáncer.
|
|
WO2022060878A1
(en)
|
2020-09-16 |
2022-03-24 |
Amgen Inc. |
Methods for treating prostate cancer
|
|
CR20230229A
(es)
|
2020-11-06 |
2023-09-05 |
Amgen Res Munich Gmbh |
Moléculas de unión a antígeno biespecíficas con múltiples dianas de selectividad aumentada
|
|
TW202233679A
(zh)
|
2020-11-06 |
2022-09-01 |
德商安美基研究（慕尼黑）公司 |
選擇性地與cldn6和cd3結合的多肽構建體
|
|
WO2022096704A1
(en)
|
2020-11-06 |
2022-05-12 |
Amgen Inc. |
Antigen binding domain with reduced clipping rate
|
|
CN116635421A
(zh)
|
2020-11-06 |
2023-08-22 |
安进公司 |
与cd3结合的多肽构建体
|
|
WO2022103781A1
(en)
|
2020-11-10 |
2022-05-19 |
Amgen Inc. |
Methods for administering a bcma x cd3 binding molecule
|
|
US11760747B2
(en)
|
2020-12-21 |
2023-09-19 |
Alkermes, Inc. |
Substituted piperidino compounds and related methods of treatment
|
|
CN117157319A
(zh)
|
2021-03-09 |
2023-12-01 |
Xencor股份有限公司 |
结合cd3和cldn6的异二聚抗体
|
|
EP4304755A1
(en)
|
2021-03-10 |
2024-01-17 |
Amgen Inc. |
Parallel chromatography systems and methods
|
|
AU2022234768A1
(en)
|
2021-03-10 |
2023-07-27 |
Amgen Inc. |
Methods for purification of recombinant proteins
|
|
KR20230154311A
(ko)
|
2021-03-10 |
2023-11-07 |
젠코어 인코포레이티드 |
Cd3 및 gpc3에 결합하는 이종이량체 항체
|
|
US12258406B2
(en)
|
2021-03-24 |
2025-03-25 |
Twist Bioscience Corporation |
Antibodies that bind CD3 Epsilon
|
|
CA3215594A1
(en)
|
2021-04-02 |
2022-10-06 |
Agnieszka KIELCZEWSKA |
Mageb2 binding constructs
|
|
AU2022253902A1
(en)
*
|
2021-04-10 |
2023-11-02 |
Genmab A/S |
Folr1 binding agents, conjugates thereof and methods of using the same
|
|
BR112023022765A2
(pt)
|
2021-05-05 |
2024-01-02 |
Immatics Biotechnologies Gmbh |
Proteínas de ligação ao antígeno que ligam especificamente o prame
|
|
AU2022269312A1
(en)
|
2021-05-06 |
2023-10-19 |
Amgen Research (Munich) Gmbh |
Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
|
|
UY39967A
(es)
|
2021-10-06 |
2023-05-15 |
Immatics Biotechnologies Gmbh |
Indicaciones para los aglutinantes anti-PRAME
|
|
CA3236194A1
(en)
|
2021-10-27 |
2023-05-04 |
Amgen Inc. |
Deep learning-based prediction for monitoring of pharmaceuticals using spectroscopy
|
|
EP4426439A1
(en)
|
2021-11-03 |
2024-09-11 |
Affimed GmbH |
Bispecific cd16a binders
|
|
WO2023079493A1
(en)
|
2021-11-03 |
2023-05-11 |
Affimed Gmbh |
Bispecific cd16a binders
|
|
EP4448108A1
(en)
|
2021-11-08 |
2024-10-23 |
Immatics Biotechnologies GmbH |
Adoptive cell therapy combination treatment and compositions thereof
|
|
KR20240155885A
(ko)
|
2022-02-25 |
2024-10-29 |
각코우호우진 쥰텐도 |
항변이 calr 항체와 다른 약제를 조합하여 이루어진 의약
|
|
WO2023209124A1
(en)
|
2022-04-29 |
2023-11-02 |
Immatics Biotechnologies Gmbh |
Mammalian display platform for multispecific antigen binding proteins
|
|
IL316597A
(en)
|
2022-05-12 |
2024-12-01 |
Amgen Res Munich Gmbh |
Multi-chain, multi-purpose, bispecific antigen-binding compounds with enhanced sensitivity
|
|
CA3258438A1
(en)
*
|
2022-06-30 |
2024-01-04 |
Modex Therapeutics, Inc. |
ANTI-SARS-CoV-2 ANTIGEN-BINDING POLYPEPTIDES, POLYPEPTIDE COMPLEXES AND THEIR METHODS OF USE
|
|
EP4587474A2
(en)
|
2022-09-14 |
2025-07-23 |
Amgen Inc. |
Bispecific molecule stabilizing composition
|
|
AU2023356984A1
(en)
|
2022-10-05 |
2025-03-20 |
Amgen Inc. |
Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
|
|
KR20250157375A
(ko)
|
2023-03-08 |
2025-11-04 |
암젠 인크 |
이중특이적 분자에 대한 제어된 빙핵 형성 동결건조 공정
|
|
AU2024302269A1
(en)
|
2023-06-14 |
2025-11-13 |
Amgen Inc. |
T cell engager masking molecules
|
|
WO2025021968A1
(en)
|
2023-07-27 |
2025-01-30 |
Immatics Biotechnologies Gmbh |
Antigen binding proteins against mageb2
|
|
WO2025043039A2
(en)
|
2023-08-22 |
2025-02-27 |
Amgen Inc. |
Methods and assemblies for efficiently packing pharmaceutical products
|
|
WO2025101672A1
(en)
|
2023-11-06 |
2025-05-15 |
City Of Hope |
Methods comprising oncolytic viruses expressing cd19t and bispecific t cell engagers
|
|
WO2025226901A1
(en)
|
2024-04-25 |
2025-10-30 |
Amgen Inc. |
Pairing of two-chain constructs
|
|
WO2025233432A1
(en)
|
2024-05-07 |
2025-11-13 |
Immatics Biotechnologies Gmbh |
Use and dosage of an antigen-binding protein comprising a tcr specific for an hla-a*02 restricted peptide
|
|
WO2025257588A1
(en)
|
2024-06-10 |
2025-12-18 |
Affimed Gmbh |
Cd16a/tumor antigen polyspecific binder for use in the treatment of immune checkpoint inhibitor resistance
|
|
WO2025259515A2
(en)
|
2024-06-11 |
2025-12-18 |
Amgen Inc. |
Combination treatment
|